After ENHERTU®, VANFLYTA® is the second innovative medicine from the Daiichi Sankyo oncology pipeline to be available in Canada Approval based on QuANTUM-First results demonstrating VANFLYTA added to chemotherapy improved overall survival TORONTO, Canada – Daiichi Sankyo’s (TSE: 4568) VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and...
treatment News
A set of expert consensus-based, quality-of-care indicators identified considerable variability in the quality of pancreatic cancer care among hospitals and may be used to evaluate and identify areas for improvement, according to a new study in the June 9 online issue of the Journal of the National Cancer Institute. Factors...
PARIS – Variant, a company dedicated to developing innovative treatments for inherited eye orphan diseases, announces the decision of the European Commission to grant Orphan Drug Designation (ODD) for VAR002 for the treatment of Leber congenital amaurosis (LCA) and Cone-rod dystrophy (CORD). The decision is based on a positive opinion...
SUMMIT, N.J. — Vascarta Inc., a healthspan focused, clinical stage biopharmaceutical company advancing safe, patient friendly therapies for pain, inflammation, and, in collaboration with the City University of New York (CUNY), announce the publication of a preclinical study demonstrating that STO-1, a first-in-class drug candidate, can selectively eliminate glioblastoma (GBM)...
BASEL, Switzerland — Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneering biotechnology company focused on developing innovative immunotherapies, today announced final data from the successful conclusion of its open-label Phase 2a clinical trial assessing the safety and tolerability of VXM01, an investigational oral anti-VEGFR-2 vaccine, in combination...
CAMBRIDGE, Mass. – VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for VBI-1901, VBI’s cancer vaccine immunotherapeutic candidate for the treatment of...
AMSTERDAM, the Netherlands & BOSTON, Mass. — VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, today announced the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) and, the European Medicines Agency (EMA) have both granted the company clearance to initiate a first-in-human clinical trial of its investigational first-in-class...
AMSTERDAM & BOSTON, Mass. — VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for VTx-002, a first-in-class vectorized antibody targeting TDP-43 pathology in amyotrophic lateral sclerosis (ALS). “ALS is a devastating and...
Among patients with previously treated Waldenström macroglobulinemia (WM), venetoclax appears to be both safe and effective regardless of CXCR4 status, according to research published in the Journal of Clinical Oncology. WM, in which MYD88 and CXCR4 mutations are common, is defined by immunoglobin M secretion in major organs, including the...
San Diego, California – The phase 2 trial PrE0405 met its primary endpoint, achieving a complete response (CR) rate of 85% in 33 patients over the age of 60 with mantle cell lymphoma (MCL) who received bendamustine and rituximab, a standard chemo-immunotherapy treatment, along with venetoclax, which is investigational in...